EU Court Ruling Jeopardizes National Healthcare Systems
German pharmacists express dismay over a European Court of Justice ruling that challenges fixed prices for prescription drugs sold by foreign providers. The decision overrides German legislative intent.
The German pharmacists' association, ABDA, has reacted with dismay to a ruling by the European Court of Justice (ECJ) in Luxembourg. The court has deemed the fixed pricing for prescription-only medicines in Germany as non-binding for foreign providers.
Friedemann Schmidt, President of ABDA, stated that the ruling from Europe's highest court undermines the clear will of the German legislature and negates decisions by Germany's top courts. "The ECJ has intervened in a policy area that, according to the European treaties, is reserved for the member states," Schmidt said.
This decision reverses a long-standing legal precedent that allowed member states discretion in healthcare matters. ABDA warns that unfettered market forces could triumph over consumer protection in healthcare and urges German politicians to re-establish legislative control. A potential solution proposed is a ban on mail-order sales of prescription drugs within Germany, which ABDA believes would be permissible under European law.
The case originated from a legal challenge questioning whether Germany's fixed drug pricing policy could be applied to companies in other EU member states shipping prescription medicines to Germany. Previously, both German lawmakers and high courts had affirmed this practice.
The existing German regulation on drug prices (AMPreisV) aimed to balance interests by protecting patients from price gouging, enabling the healthcare system's benefit-in-kind principle, and preventing harmful competition, thereby ensuring nationwide access to medicines through a network of local pharmacies.